TNFSF12
Tumor necrosis factor ligand superfamily member 12
Protein Summary
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion. This gene encodes a member of the tumor necrosis factor superfamily. It encodes a hybrid protein composed of the cytoplasmic and transmembrane domains of family member 12 fused to the C-terminal domain of family member 13. The hybrid protein is membrane anchored and presents the receptor-binding domain of family member 13 at the cell surface. It stimulates cycling in T- and B-lymphoma cell lines. [provided by RefSeq, Jul 2008]
- ENST00000293825
- ENSP00000293825
- ENSG00000239697
- APO3L
- DR3LG
- TWE-PRIL
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 0.89 | ||
ligand (protein) perturbation | 0.83 | ||
histone modification site profile | 0.76 | ||
tissue sample | 0.75 | ||
disease perturbation | 0.68 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 418.45 (req: < 5)
Gene RIFs: 213 (req: <= 3)
Antibodies: 512 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 418.45 (req: >= 5)
Gene RIFs: 213 (req: > 3)
Antibodies: 512 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0